Creative Planning purchased a new stake in shares of Embecta Corp. (NASDAQ:EMBC – Free Report) during the second quarter, Holdings Channel reports. The firm purchased 36,302 shares of the company’s stock, valued at approximately $454,000.
A number of other hedge funds and other institutional investors have also recently modified their holdings of EMBC. Iat Reinsurance Co. LTD. purchased a new position in shares of Embecta during the 2nd quarter valued at about $50,000. CWM LLC raised its position in Embecta by 773.8% in the 2nd quarter. CWM LLC now owns 9,079 shares of the company’s stock worth $113,000 after purchasing an additional 8,040 shares during the period. Cardinal Capital Management bought a new position in shares of Embecta during the first quarter valued at about $134,000. Canada Pension Plan Investment Board purchased a new stake in Embecta during the 2nd quarter valued at about $140,000. Finally, Inspire Advisors LLC lifted its position in Embecta by 12.1% in the first quarter. Inspire Advisors LLC now owns 12,341 shares of the company’s stock valued at $164,000 after purchasing an additional 1,334 shares during the last quarter. 93.83% of the stock is currently owned by hedge funds and other institutional investors.
Embecta Stock Performance
Shares of EMBC stock opened at $13.54 on Wednesday. Embecta Corp. has a fifty-two week low of $9.93 and a fifty-two week high of $19.79. The firm has a market cap of $780.85 million, a P/E ratio of 11.19 and a beta of 0.98. The business’s 50 day moving average price is $14.69 and its 200-day moving average price is $13.35.
Embecta Dividend Announcement
The business also recently declared a quarterly dividend, which was paid on Friday, September 13th. Stockholders of record on Tuesday, August 27th were given a $0.15 dividend. The ex-dividend date of this dividend was Tuesday, August 27th. This represents a $0.60 dividend on an annualized basis and a dividend yield of 4.43%. Embecta’s dividend payout ratio is currently 49.59%.
Analysts Set New Price Targets
Separately, Morgan Stanley decreased their price objective on shares of Embecta from $13.00 to $12.00 and set an “underweight” rating on the stock in a research report on Monday, July 15th.
View Our Latest Analysis on EMBC
Embecta Profile
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.
Featured Articles
- Five stocks we like better than Embecta
- Energy and Oil Stocks Explained
- Goldman Sachs Earnings Reveal Market Moves Investors Can’t Ignore
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- AMD Gains Momentum With AI: Can It Beat Expectations?
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Lithium Grab: 2 Lithium Stocks That Could Be Takeover Targets
Want to see what other hedge funds are holding EMBC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Embecta Corp. (NASDAQ:EMBC – Free Report).
Receive News & Ratings for Embecta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Embecta and related companies with MarketBeat.com's FREE daily email newsletter.